ArticleJournal of movement disorders2021
Telemedicine in an Academic Movement Disorders Center during COVID-19.
Article in Journal of movement disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Telemedicine technologies and applications in the era of COVID-19 pandemic: A systematic review.Health informatics journalPooled it
- Digital Inclusion in Parkinson's Disease: A Case-Control Study.Movement disorders clinical practice · 2025Article
- Video-based telemedicine utilization patterns and associated factors among racial and ethnic minorities in the United States during the COVID-19 pandemic: A mixed-methods scoping review.PLOS digital health · 2025Article
- Telemedicine Experiences of People Living with Amyotrophic Lateral Sclerosis at Home in South Korea.Yonsei medical journal · 2025Article
- Accelerated symptom improvement in Parkinson's disease via remote internet-based optimization of deep brain stimulation therapy: a randomized controlled multicenter trial.Communications medicine · 2025Article
- Telemedicine Use Among Older Adults During COVID-19: A Narrative Literature Review of Utilization Patterns.Telemedicine reports · 2025Review
- Neurological Examination via Telemedicine: An Updated Review Focusing on Movement Disorders.Medicina (Kaunas, Lithuania) · 2024Review
- The Importance of Digital Health Literacy in an Evolving Parkinson's Disease Care System.Journal of Parkinson's disease · 2024Review
- Parkinson's disease patients' perspective on telephone visits during the COVID-19 pandemic.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Long-Lasting Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease and Their Relatives.Movement disorders clinical practice · 2023Article
- Racial disparities in access to DBS: results of a real-world U.S. claims data analysis.Frontiers in neurology · 2023Article
- Telemedicine in the Management of Parkinson's Disease: Achievements, Challenges, and Future Perspectives.Brain sciences · 2022Article
- Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Service process factors affecting patients' and clinicians' experiences on rapid teleconsultation implementation in out-patient neurology services during COVID-19 pandemic: a scoping review.BMC health services research · 2022Article
- Moving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research.Current neurology and neuroscience reports · 2022Review
- Clinician Perceptions of the Negative Impact of Telehealth Services in the Management of Drug-Induced Movement Disorders and Opportunities for Quality Improvement: A 2021 Internet-Based Survey.Neuropsychiatric disease and treatment · 2022Article
- Parkinson's disease and Covid-19: The effect and use of telemedicine.International review of neurobiology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTelemedicine has rapidly gained momentum in movement disorder neurology during the coronavirus disease (COVID-19) pandemic to preserve clinical care while mitigating the risks of in-person visits. We present data from the rapid implementation of virtual visits in a large, academic, movement disorder practice during the COVID-19 pandemic.
methodsWe describe the strategic shift to virtual visits and retrospectively examine elements that impacted the ability to switch to telemedicine visits using historical prepandemic in-person data as a comparator, including demographics, distance driven, and diagnosis distribution, with an additional focus on patients with deep brain stimulators.
resultsA total of 686 telemedicine visits were performed over a five-week period (60% of those previously scheduled for in-office visits). The average age of participants was 65 years, 45% were female, and 73% were Caucasian. Men were more likely to make the transition (p = 0.02). Telemedicine patients lived farther from the clinic than those seen in person (66.47 km vs. 42.16 km, p < 0.001), age was not associated with making the switch, and patient satisfaction did not change. There was a significant shift in the distribution of movement disorder diagnoses seen by telemedicine compared to prepandemic in-person visits (p < 0.001). Patients with deep brain stimulators were more likely to use telemedicine (11.5% vs. 7%, p < 0.001).
conclusionTelemedicine is feasible, viable and relevant in the care of movement disorder patients, although health care disparities appear evident for women and minorities. Patients with deep brain stimulators preferred telemedicine in our study. Further study is warranted to explore these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.